Yes.
Cyrida Medical, a leading interventional medical device company, has updated its post-hearing information set and officially passed the listing hearing on the Hong Kong Stock Exchange. Syrida Medical is a leading innovative medical device company in China, covering a comprehensive product line in five treatment areas, and can provide a full set of vascular "interventional non-implantation" solutions. The company has developed a number of interventional medical devices with world-leading technologies (especially in the field of drug-coated balloons (DCB) and thrombus aspiration catheters). The company developed and launched China's first DCB product in 2016. In terms of revenue generated in 2020, the company's first peripheral DCB product dominates China's peripheral DCB market with a market share of approximately 86.9.